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Abstract 
Background: The focus of treatment of patients with peptic ulcer disease or 
gastroesophageal reflux disease has changed during the last 15 years, with a shift 
from histamine-2-receptor antagonists to proton pump inhibitors (PPIs). From 1993 
to 2000, expenditures for omeprazole (90% of total marked share of PPIs) 
increased in The Netherlands from €68 million to €230 million. In 1999, 
expenditures for pantoprazole accounted for the majority of the rest of the market 
share for PPIs. The objective of this study was to compare the efficacy and costs of 
treatment with pantoprazole and omeprazole in the Netherlands.  
Methods: First, clinical studies were reviewed that compared the efficacy of 
different dosages of omeprazole and pantoprazole. Second, data were analyzed 
from a nationwide database of drug prescriptions to determine the dosage used in 
daily practice in 1999. The data were based on a representative sample of 
approximately 40% of the Dutch community pharmacies. Third, the outcome was 
modelled of potential substitution of pantoprazole for omeprazole and 
corresponding scenarios for nationwide cost savings, using the prescription 
information from the nationwide database. Potential savings within the Dutch 
Health Care System were estimated. 
Results: The 1999 prescription data indicated that pantoprazole treatment cost a 
mean of €1.59/day, compared with €2.12/day for omeprazole. The mean cost per 
defined daily dose of omeprazole was €1.65, compared with €1.59 for 
pantoprazole. Following the Summary of Product Characteristics, treatment with 
pantoprazole appeared less costly for all indications. The projected annual cost 
savings for substituting pantoprazole for omeprazole on 90% of treatment days 
were estimated at €40.8 million. However, these projected savings may be offset 
by the costs of switching and the costs of upward dose adjustments that some 
patients may require. 
Conclusions: Based on the available documentation on effectiveness and costs of 
omeprazole and pantoprazole, pantoprazole may provide a more favourable 
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pharmacoeconomic profile than omeprazole. However this is only true if the 
substitution of omeprazole by pantoprazole can be achieved without loss of 





The focus of treatment of patients with peptic ulcer disease or gastroesophageal 
reflux disease (GERD) has changed during the last 15 years. Since the discovery of 
the role of Helicobacter pylori in the development of the condition, peptic ulcer 
disease has been treated with antibiotic eradication therapy instead of acid-
inhibitory drugs to prevent relapses [1]. Often, a proton pump inhibitor (PPI) 
comprises eradication therapy. Currently, GERD is mostly managed with PPIs 
instead of histamine-2-receptor antagonists [2]. 
Recent data show that after eradication of Helicobacter pylori, up to 60% 
of patients continue to use PPIs [3].  One explanation is that  Helicobacter pylori  
inhibits reflux oesophagitis and other acid-related disorders by inducing 
hypoacidity. Furthermore, it is suspected that PPIs are used in patients with 
persistent dyspepsia without endoscopic diagnosis of peptic ulcer or GERD and in 
peptic ulcer patients who do not achieve eradication of the condition [4,5]. 
Despite national and international guidelines (including that of the Dutch 
General Practitioners) to restrict the use of PPIs to the treatment of endoscopically 
confirmed moderate or serious GERD, the use of PPIs is growing worldwide [5]. 
Expenditures for omeprazole (90% of total marked share of PPIs) increased in The 
Netherlands from €68 million in 1993 to €230 million in 2000 [6].   
In 1999, 3 PPIs were available in the Netherlands: omeprazole, 
pantoprazole and lansoprazole. Because the vast majority of Dutch PPI 
prescriptions at this time were for omeprazole and pantoprazole, and lansoprazole 
was not approved for the eradication of Helicobacter pylori and chronic treatment 
of peptic ulcer disease in the Netherlands, we limited our analysis to omeprazole 
and pantoprazole [7,8].  
Although omeprazole and pantoprazole belong to the same therapeutic 
class, there are some differences in their pharmacologic profiles [9]. Notably, 
pantoprazole has a linear (and therefore more predictable) pharmacokinetic profile 
[10,11], less variable bioavailability [12] and a faster onset of action [13,14]. 
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Despite these differences in pharmacological profiles there may be no clinically 
relevant differences in the efficacy of omeprazole and pantoprazole. Both drugs are 
highly effective and have good tolerability and safety profiles. 
The objective of this study was to compare the efficacy and costs of 
pantoprazole and omeprazole in the treatment of patients with GERD or peptic 
ulcer disease in the Netherlands. First we reviewed clinical studies that compared 
data on the efficacy of different dosages of omeprazole and pantoprazole. Second, 
we analyzed prescription data for the Netherlands concerning dosages used in the 
daily practice. Finally, we modelled potential substitution of pantoprazole for 




Materials and Methods 
We performed a meta-analysis on the clinical efficacy of omeprazole and 
pantoprazole according to the fixed-effect model [15]. To select studies on clinical 
efficacy we searched the MEDLINE and EMBASE databases using the following 
key words: omeprazole, pantoprazole, GERD, GORD (British variation of GERD), 
reflux and (peptic) ulcer. Studies were further selected using the following criteria: 
(1) the study should present new and original work; (2) the study should compare 
omeprazole and pantoprazole under the same clinical conditions (e.g. severity of 
disease, dosing scheme); and (3) the study must be double-masked. Furthermore, 
we searched on references in detected papers. 
Two independent researchers (RMK and BAvH) identified these studies 
concerning the efficacy of omeprazole and pantoprazole. In case of disagreement 
or uncertainty, a third researcher was consulted (JRBJB). 
We used the relative risk (RR) to compare the PPIs used in the studies. The 










Where A1 and N1 represent the treatment success and number of patients using PPI 
1, respectively, and A2 and N2 represent the treatment success and number of 
patients using PPI 2 respectively. 
To pool study results, we used the weighted RR (wRR) to correct for the 


















Where W represents the weight factor given to the studies and SE2 represents the 
square of the standard error. 










Where B1 represents the failure of PPI 1 and B2 represents the failure of PPI 2. 
The 95% confidence interval (CI) was calculated using the formula: 
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As a theoretical basis for our analysis, we used the dosages for both drugs 
as specified in the manufacturers’ Summary of Product Characteristics [17,18,19]. 
These dosages were also used in the Dutch guidelines for PPI treatment [20,21]. 
For the formal calculation, we used a defined daily dose (DDD) of 20 mg for 
omeprazole and 40 mg for pantoprazole.  
Dosages of both drugs used in daily practice were derived from nationwide 
database on drug prescriptions [22,23]. These data comprise the number of days on 
treatment and dosages of PPIs prescribed by General Practitioners and medical 
specialists in the Netherlands. The data are based on a representative sample of 
approximately 40% of the Dutch community pharmacies. Data from 1999 was 
used.  
Drug prices used in the analyses were those given by the Royal Dutch 
Association for the Advancement of Pharmacy [24]. Multiplication of dosages 
used with the drug prices provided the daily practice costs for both drugs. 
Estimated costs in daily practice were combined with specific assumptions on 
potential substitution of pantoprazole for omeprazole to derive scenarios for 




The Clinical efficacy of short-term treatment of peptic ulcer and GERD is shown 
in TABLE 1 [25-33]. Data from the meta-analysis and from all individual studies 
that compared pantoprazole and omeprazole indicate no statistically significant 
difference between the PPIs. 
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 Table 1. Randomised double-masked studies comparing the efficacy after 4 weeks 
of pantoprazole 20 mg or 40 mg (P20,P40) and omeprazole 20 mg (O20) in 
patients with endoscopically established gastric ulcer, duodenal ulcer or reflux 
oesophagitis. Superior efficacy for the first product mentioned is indicated by a 
relative risk (RR) >1 
















































0.70 0.96 1.30 








0.65 0.89 1.22 








0.75 0.97 1.26 








0.77 0.99 1.28 
























0.63 0.96 1.45 
Abbreviations and symbols: CI = confidence interval; † based on interim results 
 
 
TABLE 2 [17-19,21,24] shows the costs of treatment for short-term therapy with 
omeprazole and pantoprazole for various diagnostic groups based on the 
recommendations of the Summary of Product Characteristics [17,18,19] and the 
reference prices [21,24]. The costs of treatment with omeprazole exceeded those of 
pantoprazole for symptomatic GERD and mild reflux oesophagitis over the 
duration of treatment. Together, these indications represent >60% of PPI utilization 
in the Netherlands [22]. 
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Table 2. Costs of acute treatment regimens in €* based on the Summary Product 









Ulcus duodeni 1 day at recommended dose 






Ulcus ventriculi 1 day at recommended dose 






Reflux oesophagitis 1 day at recommended dose 









1 day at recommended dose 








1 day at recommended dose 






* KNMP price list in €, January 2000 [24].. All prices in this study refer to the original branded 
product. † Recommended for grade 1 reflux oesophagitis. 
 
 
Table 3. Weighted mean cost of proton-pump inhibitors in 1999.
Drug Dosage 
regimen 
No. of Days of 
treatment [22,23] 
% of Total 
Treatment Days 
€/Day [24] Total, € 
Omeprazole 
10 mg 1x10 mg 5,256,845 6.12 1.01 5,295,704 
20 mg 2x10 mg 260,938 0.30 2.02 522,703 
 1x20 mg 55,257,873 64.33 1.65 91,275,226 
40 mg 2x20 mg 10,246,841 11.93 3.30 33,852,322 
 1x40 mg 13,772,945 16.04 3.20 44,060,099 
80 mg 2x40 mg 1,097,505 1.28 6.40 7,022,167 
Total  85,892,947 100.00  182,028,220 
Pantoprazole 
20 mg 1x20 mg 653,186 7.65 1.01 658,014 
40 mg 2x20 mg 42,754 0.50 2.02 85,647 
 1x40 mg 7,591,931 88.91 1.59 12,058,126 
80 mg 2x40 mg 250,871 2.94 3.18 796,882 
Total  8,538,742 100.00  13,598,669 
 
 
Table 4. Cost savings calculated for different % of substitution pantoprazole for 
omeprazole 
Substitution Cost savings in € 
90% 40,8 million 
80% 36,2 million 
50% 22,7 million 
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For maintenance treatment, pantoprazole 20 mg is indicated, whereas for 
omeprazole a step-up schedule of 10 to 20 or 40mg is recommended [21], so that  
the treatment costs of pantoprazole are fixed at €1.01 per day, whereas the 
treatment costs with omeprazole are at least €1.01 per day and may increase to a 
maximum of €3.30 per day. However, patients may relapse on pantoprazole 20 mg 
per day and require higher dosages of pantoprazole [21]. Therefore, it is relevant to 
consider how often patients need higher dosages of PPIs. 
Table III [22-24] shows prescriptions and costs for omeprazole and 
pantoprazole during 1999. Mean daily costs for omeprazole exceeded those for 
pantoprazole by 33.4% during the study period. For omeprazole, the DDD of 20 
mg was doubled or quadrupled on 29.2% of treatment days. In contrast, for 
pantoprazole, the DDD of 40 mg was doubled on 2.9% of treatment days. The 
mean dosage per treatment day was 26 mg for omeprazole and 40 mg for 
pantoprazole. Note that the mean cost per DDD of omeprazole (€1.65) exceeded 
that of pantoprazole (€1.59) by 4%.  
  Assuming that pantoprazole could be substituted for omeprazole on 
90% of treatment days without reducing treatment efficacy, a potential cost 
saving of €40.8 million would be expected for the Netherlands as a whole 
(0.9*85,892,947*[2.12-1.59]). Table IV summarizes the potential cost 
savings for this and 2 other scenarios. 
 
Discussion 
Our comparison of the clinical efficacy of omeprazole and pantoprazole suggests 
that only minimal differences exist between the agents for short-term treatment of 
GERD and peptic ulcer disease. In controlling GERD, PPIs are often used as long-
term medication. It is highly likely that both agents are dosed in such a way that 
GERD is controlled. Therefore, the long-term advantages of controlled GERD are 
expected to be similar for omeprazole and pantoprazole. In practice, pantoprazole 
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is often prescribed at a slightly lower dose than its indicated DDD. Omeprazole, 
however, is often prescribed at a slightly higher dose than its DDD. Costs per day 
of utilization were estimated at € 2.12 and € 1.59 for omeprazole and pantoprazole, 
respectively. Based on these estimates, our study suggest that if a patient was 
treated with a PPI, choosing pantoprazole rather than omeprazole might produce 
cost savings over the long term. These savings are related to the observed 
difference in mean dosage per treatment day (26 mg for omeprazole and 40 mg for 
pantoprazole, respectively) and the assumed possibility of switching 90% of 
patients on omeprazole to pantoprazole. 
 The plausibility of switching from omeprazole to pantoprazole can be 
derived from prescription data showing that switching already occurs [34]. These 
data indicate that over a period of 14 months, approximately 50% fewer patients 
were switched from pantoprazole to omeprazole than vice versa. 
 Some factors in our study should be considered with respect to its potential 
bias and validity, primarily with regard to the prescription data that were used. 
Possibly, omeprazole has been and is still prescribed for patients who have more 
severe disease, such as symptomatic ulcer, than that of patients taking 
pantoprazole. This may be because of developments in time – omeprazole was the 
first registered clinical available PPI – and because physicians may have favoured 
omeprazole as the drug with which they had the most experience. However, further 
analysis of the prescription data for 1999 indicated similar differences in average 
doses of omeprazole and pantoprazole are also seen in less severe indications, such 
as dyspepsia (1.17 versus 0.87 DDD, respectively). Also, these data suggested that 
pantoprazole was most often used in patients with oesophagitis (41% of 
pantoprazole vs. 32% omeprazole prescriptions). In this group, the average dose of 
omeprazole is 1.4 DDD versus 1.1 DDD of pantoprazole. Finally, the prescription 
data show that pantoprazole is used less frequently for functional disorders of the 
stomach: 19% of prescriptions for pantoprazole versus 28% for omeprazole). 
Although all this information can be used as a measure of disease severity, no 
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direct information on severity of disease was available. It is possible that 
omeprazole was used in more severe cases of each separate disease than 
pantoprazole, justifying the higher dosages of omeprazole.  
 In general, lower dosages are recommended for older patients, but double 
dosing of omeprazole for elderly patients was noted in the prescription data. This is 
not the case for pantoprazole, which may explain the observation of higher 
prescribed daily dosages for omeprazole. However, further analysis of the 
prescription data for 1999 indicated that the mean dose of omeprazole in patients 
aged >65 years (1.4 DDD), who accounted for 40% of omeprazole prescriptions, 
was similar to the overall mean dose (1.3 DDD). The dose range for omeprazole in 
the elderly has been questioned previously [35]. Differences in duration of 
treatment between age groups can be expected to be the same for both omeprazole 
and pantoprazole.  
 Some factors may cause underestimation of cost savings in our approach. 
For example, the lower drug-drug interaction potential of pantoprazole may lead to 
additional indirect cost savings [36,37]. Secondly, with more PPIs on the Dutch 
market now than in 1999 and with the introduction of generic omeprazole, prices 
may currently be lower for PPIs, potentially creating greater cost savings than 
those determined in our estimates for switching patients from omeprazole to 
pantoprazole. Finally, the relative efficacies of drugs in randomized clinical trials 
may not always predict their relative effectiveness in the general population in 
everyday practice. 
 Another possible strategy for lowering costs could be to convince 
prescribers to use 20 mg omeprazole (DDD) instead of the mean daily dose of 26 
mg that was observed in this assessment. However, it is not known whether this 
higher dosing of omeprazole may be justified. The relevance of the dosage and 
relative efficacies of different PPIs has been debated previously [8,38,39]. 
Although the evidence of expert opinions can be discussed, the guidelines from the 
National Institute for Clinical Excellence [40] do not differentiate between the 
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available PPIs except on the grounds of price and accepted indications. Concerning 
the accepted indications between omeprazole and pantoprazole there are no major 
differences in most countries [36]. 
In general, independent which PPI is chosen, the use of this class of drugs seems to 
be very cost-effective in the treatment of erosive reflux oesophagitis [41]. Other 
interventions, such as educational intervention for general practitioners, have also 
been effective for reducing community drug costs for PPIs [42].  The introduction 
of on demand use of PPIs in clinical practice (as documented for esomeprazole and 




Based on the available documentation about effectiveness and costs of omeprazole 
and pantoprazole, pantoprazole seems to provide a more favourable 
pharmacoeconomic profile than omeprazole for the treatment of peptic ulcer and 
GERD. However, this is only true if pantoprazole can be substituted for 
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